OSUCCC – James Wins National Awards for Excellence in Patient Care
The OSUCCC – James earned two national awards for excellence in patient care delivery from Press Ganey, a healthcare performance improvement organization that works with more than 41,000 healthcare facilities to improve safety, quality and experience of care. 2019 was the fourth consecutive year The James has received the Press Ganey Guardian of Excellence Award. The award recognizes health care organizations that have achieved the 95th percentile or above for performance in patient experience. The James also received the 2019 Press Ganey Pinnacle of Excellence Award, which is given to top-three performing organizations in each award category.
The James and Breast Center Gain Full ACOS Re-Accreditation
Ohio State’s cancer program received two prestigious re-accreditations after separate site surveys by components of the American College of Surgeons (ACoS). The James Cancer Hospital and Solove Research Institute earned a full three-year re-accreditation from the ACoS Commission on Cancer (ACoS-CoC), and the Stefanie Spielman Comprehensive Breast Center earned a full three-year re-accreditation from the ACoS National Accreditation Program for Breast Centers (ACoS-NAPBC).
James MICU & SICU Earn Gold Beacon Awards for Excellence
The James Medical Intensive Care Unit (MICU) and Surgical Intensive Care Unit (SICU) earned gold-level Beacon Awards for Excellence from the American Association of Critical Care Nurses (AACN). Gold is the highest Beacon Award that can be achieved. The award honors individual units that distinguish themselves by improving every facet of patient care. Units that achieve this three-year, three-level award with gold, silver or bronze designations meet national criteria consistent with AACN Magnet® Recognition, the Malcolm Baldrige National Quality Award and the National Quality Healthcare Award. This was the second Beacon Award for the SICU, which in 2016 received a silver award. The Blood and Marrow Transplantation Unit at The James earned a gold Beacon Award in 2018.
The James is Nationally Ranked for 21st Consecutive Year
U.S. News & World Report listed the James Cancer Hospital and Solove Research Institute among America’s Best Hospitals for cancer care for the 21st straight year, ranking it 20th in the nation for 2019-20 — the same ranking the hospital received for 2018-19. The hospital has moved up 17 places on the U.S. News list over the past four years. It first appeared on the list in 1999, less than a decade after opening in 1990, and has remained there since.
Advanced Practice Professional Fellowship Earns Re-Accreditation
The James Oncology & Critical Care Advanced Practice Professional (APP) Fellowship earned a three-year Accreditation with Distinction as a practice transition program from the American Nurses Credentialing Center’s (ANCC) Practice Transition Accreditation Program® (PTAP). PTAP sets the global standard for fellowship programs that transition advanced practice registered nurses (APRNs) into new practice settings. Accreditation with Distinction is the highest recognition awarded by the ANCC’s accreditation program. Among those at The James who were heavily involved with achieving the recognition were Robin Rosselet, Cindy Byrd, Kris Mathey, Michael Ailes and Denise Freeman.
Noted Cancer Expert Delivers Annual Block Lecture at The James
Elaine Fuchs, PhD, an investigator with the Howard Hughes Medical Institute and the Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development at The Rockefeller University, presented “Stem Cells in Silence, Stress and Cancer” in November 2019 as the recipient of the 24th Annual Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer. The OSUCCC – James presents the $50,000 Block Lectureship Award each year to a prominent cancer researcher who then visits Ohio State to accept the honor and lecture about his or her work. Fuchs is renowned for her research in skin biology, its stem cells and associated genetic disorders, particularly cancers.